ARDS Biomarker Monitoring Using Bioaffinity Assays
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective monitoring and treatment strategies for acute respiratory distress syndrome (ARDS) using multiple sequential biomarkers, particularly the combination of CD73 and IL-6, to assess disease severity and treatment efficacy.
Innovation Solution
A method for simultaneous determination of multiple ARDS-related biomarkers, including CD73 and IL-6, in patient samples, using bioaffinity assays and thin layer chromatography to monitor changes over time, enabling optimized treatment by administering therapeutically active agents based on biomarker activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If multiple sequential biomarkers are used to monitor ARDS, then monitoring precision is improved, but device complexity and cost increase
Solution Approach 1:
The patent segments the monitoring process into discrete time points (e.g., admission, 24-48 hours, 72-96 hours) with specific biomarker panels at each stage. This allows comprehensive monitoring precision through multiple biomarkers while managing complexity by structuring the assessment in organized phases rather than continuous complex monitoring.
Solution Approach 2:
The patent employs a universal set of biomarkers (CD73, IL-6, IL-8, CRP, procalcitonin) that can be measured using standardized laboratory techniques across different time points and patient conditions. This multi-functional approach allows the same biomarker panel to assess disease severity, monitor treatment response, and predict outcomes, improving precision without proportionally increasing device complexity.
2Loss of information
If multiple biomarkers are measured simultaneously, then information completeness is improved, but measurement time and cost increase
Solution Approach 1:
The patent performs preliminary biomarker measurements at admission to establish baseline values and risk stratification before initiating treatment. This preliminary action allows clinicians to prepare appropriate treatment protocols in advance, reducing the need for extensive repeated measurements later and optimizing the timing of comprehensive biomarker panels.
Solution Approach 2:
The patent implements periodic biomarker measurement at standardized time intervals (24-48 hours, 72-96 hours) rather than continuous monitoring. This periodic approach ensures complete information about disease progression while minimizing measurement time and resource utilization compared to continuous assessment.
3Reliability
If biomarker-guided treatment is implemented, then treatment efficacy is improved, but treatment complexity increases
Solution Approach 1:
The patent employs dynamic treatment adjustment based on biomarker trends over time. Treatment protocols are modified according to the direction and magnitude of biomarker changes (e.g., increasing CD73 activity indicates improvement and may allow treatment de-escalation). This dynamic approach improves treatment efficacy by adapting to patient response while maintaining manageable complexity through pre-established adjustment algorithms.
Solution Approach 2:
The patent implements feedback loops where biomarker measurements inform subsequent treatment decisions. Clinicians receive feedback on biomarker trends (e.g., IL-6 levels indicating inflammation, CRP showing recovery) and adjust therapy accordingly. This feedback mechanism enhances treatment efficacy by creating a closed-loop system while managing complexity through standardized feedback interpretation guidelines.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for precise monitoring of ARDS severity and treatment efficacy, enabling healthcare providers to optimize patient care and reduce mortality by using biomarker changes to guide pharmacological interventions.
Implementation Method 1
a set of capture binders immobilised to a solid support or capable of being immobilised to a solid support, wherein each capture binder is specific for a certain biomarker to be determined
Implementation Method 2
a set of labelled bioaffinity components, wherein each such labelled bioaffinity component has a bioaffinity specific for a certain immobilised biomarker
Implementation Method 3
determining the activities of the biomarkers in said sample by using thin layer chromatography
Data Source
AI summary
This invention concerns methods for monitoring the development of and for treatment of ARDS in a patient. The method for monitoring the development of ARDS is based on comparing the level or activity of the biomarkers obtained in a sample drawn at a later point of time to the levels or activities of the same biomarkers in a sample drawn at a previous point of time. A favorable change in the level or activity of a certain biomarker represents a regression of the disease (recovery of the patient), and, conversely, an adverse change in the level or activity of a certain biomarker represents a worsening of the disease. If, for example, the level or activity for one or more of the biomarkers monitored discontinues to show a favorable change or starts to show an unfavorable change, the treatment of the patient is enhanced by administering a therapeutically active agent useful in the treatment of ARDS. The invention concerns further a method for simultaneous determination of a multiple of biomarkers in a sample from a patient, wherein said biomarkers are related to ARDS. The level or the activity of the biomarkers is determined. The invention also concerns a diagnostic kit useful for carrying out the method, particularly a kit comprising a chip, such as a microarray suitable for use in biochip technology.